Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian CancerCancer
- Interventions
- Drug: CPC634 (CriPec® docetaxel)
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- Cristal Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT03742713
- Locations
- 🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
🇳🇱Dijklander Hospital, Hoorn, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
A Study of CriPec® Docetaxel Given to Patients With Solid Tumours
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Cristal Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT02442531
- Locations
- 🇳🇱
UMC Groningen, Groningen, Netherlands
🇧🇪University Hospital Leuven, Leuven, Belgium
🇳🇱VUMC Amsterdam, Amsterdam, Netherlands
© Copyright 2025. All Rights Reserved by MedPath